<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Molina, Carlos A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results of a Randomized, Multi-Center Safety Trial of Perflutren Lipid Microspheres: TUCSON</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">Microspheres that are combined with systemic tPA and rational transcranial Doppler show promise as a recanalization tool in patients with acute ischemic stroke if administered within 3 hours of stroke onset. This article discusses results from the Transcranial Ultrasound in Clinical SONolyis [TUCSON; NCT00504842] trial, identifying 1.4 mL of MRX-801 perflutren lipid microspheres as a safe dose that produces higher rates of recanalization (67% vs 33%; p=0.22) compared with controls.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>